In the online “early view” section of the journal Cancer there is a new research article proposing that using three currently-used immunohistochemical breast markers in a group of patients who received neoadjuvant chemotherapy, doctors can sub-type cancers similar to those described by molecular profiling.  They also suggest these sub-types are associated with different responses to treatment and overall survival. [...]

Question: I am in the Uk and my wife (42) has Grade 2 breast cancer 2 nodes er+ and pr + my question is about her path report: the HER2 was registered at 2.2 after the FISH test – does this mean that herceptin will work or is it to borderline to benefit? As the [...]